Table 7. Costs of disease managements (in € for 2013)a.
| Phases of treatment | Work-up for tumor extension | Surgery | Chemo-therapy | Radio-therapy | Other treatment | Post-treatment surveillance | RRePS network organization and histological reviewb | Total |
|---|---|---|---|---|---|---|---|---|
| ID Sarcoma / FD Sarcoma | ||||||||
| Mean (%) | 216 (3%) | 2,033 (31%) | 1,389 (21%) | 1,957 (31%) | 0 (0%) | 570 (9%) | 331 (5%) | 6,497 (100%) |
| Min-Max | 0–529 | 0–8,536 | 0–28,319 | 0–6,177 | 0–0 | 37–1,789 | 331–331 | 595–38,711 |
| ID Sarcoma / FD Intermediate malignant tumor | ||||||||
| Mean (%) | 68 (3%) | 1,830 (69%) | 0 (0%) | 0 (0%) | 0 (0%) | 442 (16%) | 331 (12%) | 2,671 (100%) |
| Min-Max | 0–271 | 0–3,565 | 0–0 | 0–0 | 0–0 | 126–560 | 331–331 | 890–4,708 |
| ID Sarcoma / FD GIST | ||||||||
| Mean (%) | 195 (1%) | 1,493 (5%) | 27,716 (91%) | 0 (0%) | 0 (0%) | 510 (2%) | 331 (1%) | 30,244 (100%) |
| Min-Max | 195–195 | 0–3,903 | 27,716–27,716 | 0–0 | 0–0 | 510–510 | 331–331 | 28,752–32,654 |
| ID Sarcoma / FD Desmoid tumor | ||||||||
| Mean (%) | 70 (5%) | 386 (26%) | 0 (0%) | 0 (0%) | 107 (7%) | 575 (39%) | 331 (23%) | 1,469 (100%) |
| Min-Max | 0–280 | 0–1,544 | 0–0 | 0–0 | 0–215 | 340–840 | 331–331 | 885–3,209 |
| ID Sarcoma / FD Non-sarcoma malignant tumor | ||||||||
| Mean (%) | 634 (7%) | 1,707 (19%) | 4,043 (44%) | 1,770 (19%) | 0 (0%) | 630 (7%) | 331 (4%) | 9,115 (100%) |
| Min-Max | 0–1,407 | 0–7,998 | 0–26,428 | 0–6,694 | 0–0 | 37–4,433 | 331–331 | 368–32,903 |
| ID Sarcoma / FD Benign tumor | ||||||||
| Mean (%) | 7 (2%) | 60 (15%) | 0 (0%) | 0 (0%) | 0 (0%) | 4 (1%) | 331 (82%) | 402 (100%) |
| Min-Max | 0–280 | 0–2,569 | 0–0 | 0–0 | 0–0 | 0–280 | 331–331 | 331–2,900 |
| ID Intermediate malignant tumor / FD Sarcoma | ||||||||
| Mean (%) | 374 (3%) | 4,245 (28%) | 5,664 (38%) | 3,430 (23%) | 0 (0%) | 880 (6%) | 331 (2%) | 14,924 (100%) |
| Min-Max | 144–529 | 3,565–6,965 | 0–28,319 | 0–6,177 | 0–0 | 585–1,169 | 331–331 | 4,903–38,710 |
| ID Intermediate malignant tumor / FD Intermediate malignant tumor | ||||||||
| Mean (%) | 81 (4%) | 1,514 (70%) | 0 (0%) | 0 (0%) | 0 (0%) | 236 (11%) | 331 (15%) | 2,162 (100%) |
| Min-Max | 0–280 | 0–3,565 | 0–0 | 0–0 | 0–0 | 37–560 | 331–331 | 411–4,709 |
| ID Intermediate malignant tumor / FD Desmoid tumor | ||||||||
| Mean (%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 215 (19%) | 560 (51%) | 331 (30%) | 1,106 (100%) |
| Min-Max | 0–0 | 0–0 | 0–0 | 0–0 | 215–215 | 560–560 | 331–331 | 1,106–1,106 |
| ID Intermediate malignant tumor / FD Non-sarcoma malignant tumor | ||||||||
| Mean (%) | 97 (1%) | 3,619 (30%) | 7,278 (60%) | 0 (0%) | 0 (0%) | 679 (6%) | 331 (3%) | 12,004 (100%) |
| Min-Max | 0–195 | 0–7,238 | 0–14,556 | 0–0 | 0–0 | 37–1,322 | 331–331 | 368–23,641 |
| ID Intermediate malignant tumor / FD Benign tumor | ||||||||
| Mean (%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 331 (100%) | 331 (100%) |
| Min-Max | 0–0 | 0–0 | 0–0 | 0–0 | 0–0 | 0–0 | 331–331 | 331–331 |
| ID GIST / FD Sarcoma | ||||||||
| Mean (%) | 191 (4%) | 1,360 (25%) | 2,447 (45%) | 412 (8%) | 0 (0%) | 663 (12%) | 331 (6%) | 5,404 (100%) |
| Min-Max | 144–195 | 0–8,536 | 0–14,556 | 0–6,177 | 0–0 | 390–780 | 331–331 | 1,110–15,861 |
| ID GIST / FD GIST | ||||||||
| Mean (%) | 191 (1%) | 1,245 (4%) | 27,710 (92%) | 0 (0%) | 0 (0%) | 538 (2%) | 331 (1%) | 30,015 (100%) |
| Min-Max | 170–195 | 0–3,903 | 27,680–27,716 | 0–0 | 0–0 | 510–680 | 331–331 | 28,752–32,655 |
| ID GIST / FD Desmoid tumor | ||||||||
| Mean (%) | 28 (3%) | 0 (0%) | 0 (0%) | 0 (0%) | 92 (11%) | 388 (46%) | 331 (40%) | 839 (100%) |
| Min-Max | 0–195 | 0–0 | 0–0 | 0–0 | 0–215 | 340–510 | 331–331 | 670–1,250 |
| ID GIST / FD Non-sarcoma malignant tumor | ||||||||
| Mean (%) | 595 (8%) | 2,462 (32%) | 3,386 (44%) | 0 (0%) | 0 (0%) | 874 (12%) | 331 (4%) | 7,648 (100%) |
| Min-Max | 195–1,284 | 0–12,312 | 0–14,556 | 0–0 | 0–0 | 780–972 | 331–331 | 1,497–16,861 |
| ID GIST / FD Benign tumor | ||||||||
| Mean (%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 9 (3%) | 331 (97%) | 340 (100%) |
| Min-Max | 0–0 | 0–0 | 0–0 | 0–0 | 0–0 | 0–75 | 331–331 | 331–406 |
| ID Desmoid tumor / FD Sarcoma | ||||||||
| Mean (%) | 144 (3%) | 3,903 (78%) | 0 (0%) | 0 (0%) | 0 (0%) | 585 (12%) | 331 (7%) | 4,963 (100%) |
| Min-Max | 144–144 | 3,903–3,903 | 0–0 | 0–0 | 0–0 | 585–585 | 331–331 | 4,963–4,963 |
| ID Desmoid tumor / FD Desmoid tumor | ||||||||
| Mean (%) | 57 (5%) | 127 (11%) | 0 (0%) | 0 (0%) | 140 (11%) | 564 (46%) | 331 (27%) | 1,219 (100%) |
| Min-Max | 0–280 | 0–1,544 | 0–0 | 0–0 | 0–215 | 340–840 | 331–331 | 671–3,209 |
| ID Desmoid tumor / FD Benign tumor | ||||||||
| Mean (%) | 0 (0%) | 309 (48%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 331 (52%) | 640 (100%) |
| Min-Max | 0–0 | 0–1,544 | 0–0 | 0–0 | 0–0 | 0–0 | 331–331 | 331–1,874 |
| ID Non-sarcoma malignant tumor / FD Sarcoma | ||||||||
| Mean (%) | 185 (3%) | 2,030 (29%) | 2,009 (28%) | 1,681 (23%) | 0 (0%) | 838 (12%) | 331 (5%) | 7,073 (100%) |
| Min-Max | 144–195 | 0–5,852 | 0–14,556 | 0–6,177 | 0–0 | 160–1,789 | 331–331 | 915–27,028 |
| ID Benign tumor / FD Sarcoma | ||||||||
| Mean (%) | 215 (4%) | 1,946 (35%) | 74 (1%) | 2,599 (47%) | 0 (0%) | 394 (7%) | 331 (6%) | 5,559 (100%) |
| Min-Max | 0–456 | 0–5,519 | 0–2,374 | 6,177 | 0–0 | 37–877 | 331–331 | 595–12,840 |
| ID Benign tumor / FD Intermediate malignant tumor | ||||||||
| Mean (%) | 92 (5%) | 1,309 (70%) | 0 (0%) | 0 (0%) | 0 (0%) | 140 (7%) | 331 (18%) | 1,872 (100%) |
| Min-Max | 0–280 | 0–1,837 | 0–0 | 0–0 | 0–0 | 37–560 | 331–331 | 410–2,434 |
| ID Benign tumor / FD GIST | ||||||||
| Mean (%) | 195 (1%) | 0 (0%) | 27,716 (96%) | 0 (0%) | 0 (0%) | 510 (2%) | 331 (1%) | 28,752 (100%) |
| Min-Max | 195–195 | 0–0 | 27,716–27,716 | 0–0 | 0–0 | 510–510 | 331–331 | 28,752–28,752 |
| ID Benign tumor / FD Desmoid tumor | ||||||||
| Mean (%) | 76 (6%) | 125 (9%) | 0 (0%) | 0 (0%) | 176 (13%) | 672 (48%) | 331 (24%) | 1,380 (100%) |
| Min-Max | 0–280 | 0–1,370 | 0–0 | 0–0 | 0–215 | 433–840 | 331–331 | 872–2,457 |
| ID Benign tumor / FD Non-sarcoma malignant tumor | ||||||||
| Mean (%) | 1,108 (4%) | 0 (0%) | 26,428 (88%) | 1,523 (5%) | 0 (0%) | 722 (2%) | 331 (1%) | 30,112 (100%) |
| Min-Max | 1,108–1,108 | 0–0 | 26,428–26,428 | 1,523–1,523 | 0–0 | 722–722 | 331–331 | 30,112–30,112 |
| ID Sarcoma | ||||||||
| Mean (%) | 216 (4%) | 2,034 (33%) | 1,389 (23%) | 1,957 (31%) | 0 (0%) | 570 (9%) | N/A | 6,166 (100%) |
| Min-Max | 0–529 | 0–8,536 | 0–28,319 | 0–6,177 | 0–0 | 37–1,789 | N/A | 264–38,380 |
| ID Intermediate malignant tumor | ||||||||
| Mean (%) | 81 (4%) | 1,514 (83%) | 0 (0%) | 0 (0%) | 0 (0%) | 236 (13%) | N/A | 1,831 (100%) |
| Min-Max | 0–280 | 0–3,565 | 0–0 | 0–0 | 0–0 | 37–560 | N/A | 80–4,378 |
| ID GIST | ||||||||
| Mean (%) | 191 (1%) | 1,245 (4%) | 27,710 (93%) | 0 (0%) | 0 (0%) | 538 (2%) | N/A | 29,684 (100%) |
| Min-Max | 170–195 | 0–3,903 | 27,680–27,716 | 0–0 | 0–0 | 510–680 | N/A | 28,421–32,324 |
| ID Desmoid tumor | ||||||||
| Mean (%) | 57 (6%) | 127 (14%) | 0 (0%) | 0 (0%) | 140 (16%) | 564 (64%) | N/A | 888 (100%) |
| Min-Max | 0–280 | 0–1,544 | 0–0 | 0–0 | 0–215 | 340–840 | N/A | 341–2,878 |
| ID Non-sarcoma malignant tumor | ||||||||
| Mean (%) | 624 (7%) | 1,779 (20%) | 4,335 (48%) | 1,616 (18%) | 0 (0%) | 647 (7%) | N/A | 9,021 (100%) |
| Min-Max | 0–1,407 | 0–12,312 | 0–26,428 | 0–6,694 | 0–0 | 37–4,433 | N/A | 37–32,572 |
| ID Benign tumor | ||||||||
| Mean (%) | 6 (8%) | 62 (86%) | 0 | 4 (6%) | 0 | 0 | N/A | 72 |
| Min-Max | 0–280 | 0–2,569 | 0–0 | 0–280 | 0 | 0 | N/A | 0–2,569 |
aBased on hypothetical resources used according to the characteristics and disease of the patients from the RRePS network (2010) and using national and international guidelines. Due to budgetary constraints, the costs of disease management for patients with a concordant diagnosis were estimated from the final diagnosis of the patients with a discordant diagnosis, whose sample size was smaller than the concordant cases.
bCost of RRePS network organization (€102 per patient) and Histological review (€228 per patient) included.
Abbreviations: ID: initial diagnosis, FD: final diagnosis, and N/A: not applicable.